依普利酮国内售价多少呢？

(Eplerenone, Inspra) is a selective aldosterone inhibitor originally developed by Pharmacia (Pfizer) and approved in the United States in October 2002 for the treatment of hypertension and congestive heart failure.

Eplerenone selectively acts on aldosterone receptors and is highly selective for mineralocorticoid receptors, but has less effect on androgen and progesterone receptors. Its affinity for mineralocorticoids is 15 to 20 times that of spironolactone, while its affinity for androgen and progesterone receptors is 500 times smaller than that of spironolactone, so sex hormone-related adverse reactions are less likely to occur.

In the overall population, blood pressure levels gradually increase with age, and systolic blood pressure is more obvious. However, after the age of 50, diastolic blood pressure shows a downward trend, and pulse pressure also increases. In recent years, people's understanding of the role of multiple risk factors for cardiovascular disease and the protection of target organs of the heart, brain, and kidneys has continued to deepen. The diagnostic criteria for hypertension have also been continuously adjusted. On the basis of improving lifestyle, it is recommended to use 24-hour long-acting antihypertensive drugs to control blood pressure.

The dosage for treating high blood pressure in adults is as follows: Eplerenone can be used alone or in combination with other antihypertensive drugs. Initial dose: 50 mg orally once daily, Maintenance dose: 50 mg orally once or twice daily, Maximum dose: 100 mg/day. Obvious antihypertensive effects appear within four weeks of taking the drug. Patients whose blood pressure responds inadequately to the initial dose may be increased to 50 mg twice daily.

Eplerenone is not currently on the market in China, so there is no relevant domestic price. Since the original drug produced in the United States is usually more expensive, patients can choose to buy the Indian version of the generic eplerenone, 50mg*100 tablets, with a price equivalent to about 500 US dollars in RMB.

Hyperkalemia may occur; the risk of hyperkalemia is increased with renal impairment, proteinuria, diabetes mellitus, and in patients concurrently taking ACE (angiotensin-converting enzyme) inhibitors, angiotensin II inhibitors, NSAIDs, or moderate CYP3A inhibitors. Monitor closely for hyperkalemia; serum potassium increased dose-related during clinical trials. As hyperkalemia develops, dose reduction or treatment interruption may be necessary. If concomitant treatment with a moderate CYP3A4 inhibitor cannot be avoided, reduce the eplerenone dose. It is contraindicated in patients with potassium greater than 5.5 meq/L at the beginning of treatment.